A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

NCT07672561 | Recruiting Phase 3

• 1 other identifier: WENDA890PSO-003
• Study Type: interventional
• Target: 375
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.

Conditions

Moderate to Severe Plaque Psoriasis

Outcome Measures

Primary Outcomes (2)

• Percentage of Participants Who Achieved Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) at Weeks 16

  Screening up to Week 16

• Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 16

  Screening up to Week 16

Secondary Outcomes (4)

• Percentage of Participants Who Achieved Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) at Weeks 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

  Screening up to Week 52

• Percentage of Participants Achieving PASI 90 Score at Weeks 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

  Screening up to Week 52

• Percentage of Participants Achieving PASI 100 Score at at Weeks 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

  Screening up to Week 52

• Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at at Weeks 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

  Screening up to Week 52

Study Arms (2)

Group 1:WD-890

EXPERIMENTAL

Drug:WD-890 WD-890 tablet will be administered orally.

Drug: Drug:WD-890

Group 2: Placebo

PLACEBO COMPARATOR

Drug: Placebo Placebo tablet will be administered orally.

Drug: Drug: placebo

Interventions

Drug:WD-890 DRUG

WD-890 tablet will be administered orally.

Group 1:WD-890

Drug: placebo DRUG

Placebo tablet will be administered orally.

Group 2: Placebo

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female participant aged 18 to 75 years(inclusive)at the time of informed consent.
• Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.
• Body surface area (BSA) ≥10%, Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization

You may not qualify if:

• Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, inverse, pustular,or drug induced psoriasis.)
• Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted
• Class III or IV congestive heart failure by New York Heart Association Criteria

Sponsors & Collaborators

• Zhejiang Wenda Pharma Technology LTD.: lead

Study Sites (1)

Hospital of Dermatology, Chinese Academy of Medical Sciences

Nanjing, Jiangsu, 210042, China

RECRUITING

Central Study Contacts

Lu Qianjin

CONTACT

+8613787097676; qianlu5860@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 8, 2026
• First Posted: June 29, 2026
• Study Start: March 18, 2026
• Primary Completion (Estimated): November 30, 2026
• Study Completion (Estimated): July 30, 2027
• Last Updated: June 29, 2026

Record last verified: 2026-06

Locations

CN (1)